Molecular responses at 3 and 6 months after switching to a second-generation tyrosine kinase inhibitor are complementary and predictive of long-term outcomes in patients with chronic myeloid leukemia who fail imatinib

✍ Scribed by Boquimpani, Carla; Schaffel, Rony; Biasoli, Irene; Bendit, Israel; Spector, Nelson

• Book ID: 126660233
• Publisher: Informa plc
• Year: 2014
• Tongue: English
• Weight: 715 KB
• Volume: 56
• Category: Article
• ISSN: 1042-8194
• DOI: 10.3109/10428194.2014.974047